In the 18 months since Douglas Williams became EVP of R&D at Biogen Idec Inc. (NASDAQ:BIIB), the company has plumped its Phase II pipeline by advancing existing programs and in-licensing new compounds. Williams has filled out the R&D leadership team and is now turning to rekindling target discovery, which had long lain dormant at the company. (A) Under review in U.S. and EU. A standard